Pharmaceutical company Servier has selected Pall Corp as an exclusive technology and services provider for its biomanufacturing facility in Gidy, France.

Pall Biotech end-to-end solutions will be used for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins, resulting in increased speed to market and reduced customer costs. The facility is part of Servier’s Bio-S project which is focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale.

The Bio-S project at the Gidy facility includes production lines to support internal production needs with up to 2000L bioreactor capacity that can be run in a parallel format. The Bio-S unit aligns various activities, including a development workshop dedicated to monoclonal antibody processes (bio-engineering) which will be operational by 2019. The rest of the unit will be operational in 2020.

“We are honoured to have been chosen and look forward to delivering comprehensive and scalable biomanufacturing solutions from upstream to downstream and through to fill and finish, as well as process development service expertise,” said Ed Hoare, vice president & general manager at Pall Biotech. “We have dedicated a great deal of resources to become more than just a supplier and will act as a co-development partner for all customer production steps.”

“The Bio-S project in Gidy is the beginning of an industrial solution for biomanufacturing in France, offering an innovative path for critical oncology therapies, one of the main strategic priorities for Servier,” said Renaud Bessière, director of the Bio-S Project at Servier. “We selected Pall Biotech as our single supplier because of their capacity to deliver the complete suite of development and manufacturing equipment, including an automation package, assurance of consumables supply and technical support under a well-defined project execution plan.”

For a video of Servier’s new facility click here